Role of Uremic Toxins in Mild Cognitive Impairment in Chronic Kidney Disease (MOMENTUM)
Investigator-initiated, Multicentre, International, Cross-sectional and Longitudinal Clinical Study Elucidating the Pathophysiology of Mild Cognitive Impairment in Chronic Kidney Disease With a Focus on the Role of Uremic Toxins
MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.
The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
- 行動:MoCA Test
- 診断テスト:Laboratory tests
- 診断テスト:Non-contrast-enhanced brain MRI
- 行動:Comprehensive neuropsychological test battery
- 行動:Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section
- 行動:Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections
- 行動:Questionnaires
- 行動:New MCI-CKD QoL Questionnaire
詳細な説明
Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.
Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.
Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.
As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.
Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.
The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Matias Trillini, M.D.
- 電話番号:+390354535411
- メール:matias.trillini@marionegri.it
研究場所
-
-
-
Derby、イギリス、DE22 3NE
- University Hospitals of Derby and Burton NHS Foundation Trust
-
コンタクト:
- Nicholas Selby
- 電話番号:+44(0)1332724665
- メール:nicholas.selby@nottingham.ac.uk
-
-
-
-
-
Naples、イタリア、80131
- AOU University of Campania "Luigi Vanvitelli"
-
コンタクト:
- Alessandra Perna
- 電話番号:+390815666822
- メール:alessandra.perna@unicampania.it
-
-
BG
-
Ranica、BG、イタリア、24020
- Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
-
コンタクト:
- Matias Trillini, M.D.
- 電話番号:+390354535411
- メール:matias.trillini@marionegri.it
-
-
-
-
-
Lausanne、スイス、1005
- Centre Hospitalier Universitaire Vaudois
-
コンタクト:
- Menno Pruijm, Prof.
- 電話番号:+41(0)213141131
- メール:Menno.Pruijm@chuv.ch
-
-
-
-
-
Pamplona、スペイン、31008
- Clínica Universidad de Navarra
-
コンタクト:
- Nuria Garcia Fernandez, MD PhD
- 電話番号:+34948255400
- メール:nrgarcia@unav.es
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Male or female aged 40-75 years at time of screening;
- Availability for longitudinal follow-up;
- Signed informed consent
Specifically for CKD participants:
- CKD stage G3a/G3b, or stage G4-G5 without kidney replacement therapy, or stage G5 undergoing hemodialysis (HD) for more than 3 months;
- MoCA score in the range [18-25];41
Specifically for controls:
-
Normal renal function:
- For controls aged < 65 years, eGFR ≥ 90 mL/min/1.73 m2;
- For controls aged ≥ 65 years, eGFR ≥ 60 mL/min/1.73 m2.
-
No detectable proteinuria at screening (negative urine dipstick);
-
MoCA score ≥ 26/30.
Exclusion Criteria
- Contraindication to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, aneurysm clips, or other MRI-incompatible devices, or inability to undergo MRI;
- Pre-existing neurological disorders known to affect cognitive function (e.g., dementia, Parkinson's disease, multiple sclerosis, epilepsy or neurodegenerative disorders);
- History of ischemic or hemorrhagic stroke and/or previous brain surgery;
- History of severe traumatic brain injury;
- Treated or untreated clinically significant depressive disorder that, in the investigator's judgment, may interfere with cognitive assessment;
- Recent hospitalization for acute events within the last 3 months, except for percutaneous transluminal angioplasty (PTA) of fistula, catheter replacement and elective hospitalizations;
- Serious acute illness within the last 3 months;
- Active solid tumors with or without metastasis;
- Inflammatory bowel disease;
- Systemic corticosteroid treatment for > 6 months at a prednisone-equivalent dose > 10 mg/day;
- Planned pregnancy during the 18-month follow-up period;
Specifically for CKD patients:
- Peritoneal dialysis;
- Kidney transplantation at enrolment;
Specifically for controls:
● Any chronic clinically significant condition, except for hypertension treated with < 3 antihypertensive drugs.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Group 1
Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
実験的:Group 2
Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR < 30 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
実験的:Group 3
Patients with CKD stage G5 on chronic hemodialysis (eGFR < 15 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
実験的:Group 4
Healthy controls |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.
時間枠:Baseline (Visit 2, Day 0)
|
Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately. |
Baseline (Visit 2, Day 0)
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Norberto Perico, M.D.、Istituto Di Ricerche Farmacologiche Mario Negri
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- MOMENTUM
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。